Immunogenicity

In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
Seohyun Kim, Seong A Kim, Gi-Hoon Nam, Yeonsun Hong, Gi Beom Kim, Yoonjeong Choi, Seokyoung Lee, Yuri Cho, Minsu Kwon, Cherlhyun Jeong, Sehoon Kim, In-San Kim

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e001481; DOI: 10.1136/jitc-2020-001481
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)
Craig L Slingluff, Jr., Gina R Petroni, Kimberly A Chianese-Bullock, Nolan A Wages, Walter C Olson, Kelly T Smith, Kathleen Haden, Lynn T Dengel, Anna Dickinson, Caroline Reed, Elizabeth M Gaughan, William W Grosh, Varinder Kaur, Nikole Varhegyi, Mark Smolkin, Nadejda V Galeassi, Donna Deacon, Emily H Hall

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e000934; DOI: 10.1136/jitc-2020-000934
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Razan Alzeibak, Tatiana A. Mishchenko, Natalia Y. Shilyagina, Irina V. Balalaeva, Maria V. Vedunova, Dmitri V. Krysko

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e001926; DOI: 10.1136/jitc-2020-001926
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
Peter J DeMaria, Katherine Lee-Wisdom, Renee N Donahue, Ravi A Madan, Fatima Karzai, Angie Schwab, Claudia Palena, Caroline Jochems, Charalampos Floudas, Julius Strauss, Jennifer L Marté, Jason Mark Redman, Eva Dombi, Brigitte Widemann, Borys Korchin, Tatiana Adams, Cesar Pico-Navarro, Christopher Heery, Jeffrey Schlom, James L Gulley, Marijo Bilusic

Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) e003238; DOI: 10.1136/jitc-2021-003238
Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
Luis Enrique Munoz, Lei Huang, Ramireddy Bommireddy, Richa Sharma, Lenore Monterroza, Rohini N. Guin, Sarah G. Samaranayake, Christopher D. Pack, Sampath Ramachandiran, Shaker J.C. Reddy, Mala Shanmugam, Periasamy Selvaraj

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e002614; DOI: 10.1136/jitc-2021-002614
Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis
Yifei Ma, Nianqi Liu, Youlong Wang, Jiling Zeng, Ying-Ying Hu, Wu Hao, Huazheng Shi, Pengfei Zhu, Jun Lv, Wei Fan, Xinjia Wang

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003712; DOI: 10.1136/jitc-2021-003712
Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response
Lele Zhang, Jiacheng Huang, Xiaona Chen, Caixu Pan, Yong He, Rong Su, Danjing Guo, Shengyong Yin, Shuai Wang, Lin Zhou, Jianxiang Chen, Shusen Zheng, Yiting Qiao

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003132; DOI: 10.1136/jitc-2021-003132
HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial
Noor Alida Maria Bakker, Jossie Rotman, Marc van Beurden, Henry J MAA Zijlmans, Maartje van Ruiten, Sanne Samuels, Bastiaan Nuijen, Jos Beijnen, Karin De Visser, John Haanen, Ton Schumacher, Tanja D de Gruijl, Ekaterina S Jordanova, Gemma G Kenter, Joost H van den Berg, Nienke E van Trommel

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002547; DOI: 10.1136/jitc-2021-002547
Recombinant Mycobacterium smegmatis delivering a fusion protein of human macrophage migration inhibitory factor (MIF) and IL-7 exerts an anticancer effect by inducing an immune response against MIF in a tumor-bearing mouse model
Hyein Jeong, So-Young Lee, Hyejun Seo, Bum-Joon Kim

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003180; DOI: 10.1136/jitc-2021-003180
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
Sapna P Patel, Gina R Petroni, Jason Roszik, Walter C Olson, Nolan A Wages, Kimberly A Chianese-Bullock, Mark Smolkin, Nikole Varhegyi, Elizabeth Gaughan, Kelly T Smith, Kathleen Haden, Emily H Hall, Sacha Gnjatic, Patrick Hwu, Craig L Slingluff

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003220; DOI: 10.1136/jitc-2021-003220

Main menu

Immunogenicity

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immunogenicity

Pages